StockData
Viatris Inc logo

Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.28−0.17 (-0.83%)

Close on Nov 18, 2026Market cap $23.29BP/E –Yield 2.37%

Viatris revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Viatris's revenue for the twelve months ending Jun 30, 2026 was $14.74B, up 4.4% year over year. For fiscal 2025 it was $14.30B, down 3.0% from the year before. The highest annual figure on record is $17.89B in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.30B-3.0%
FY2024Dec 31, 2024$14.74B-4.5%
FY2023Dec 31, 2023$15.43B-5.1%
FY2022Dec 31, 2022$16.26B-9.1%
FY2021Dec 31, 2021$17.89B+49.7%
FY2020Dec 31, 2020$11.95B+3.9%
FY2019Dec 31, 2019$11.50B+0.6%
FY2018Dec 31, 2018$11.43B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.76B+4.9%
Q1 FY2026Mar 31, 2026$3.52B+8.1%
Q4 FY2025Dec 31, 2025$3.70B+5.0%
Q3 FY2025Sep 30, 2025$3.76B+0.2%
Q2 FY2025Jun 30, 2025$3.58B-5.6%
Q1 FY2025Mar 31, 2025$3.25B-11.2%
Q4 FY2024Dec 31, 2024$3.53B-8.1%
Q3 FY2024Sep 30, 2024$3.75B-4.8%
Q2 FY2024Jun 30, 2024$3.80B-3.1%
Q1 FY2024Mar 31, 2024$3.66B-1.8%
Q4 FY2023Dec 31, 2023$3.84B-1.0%
Q3 FY2023Sep 30, 2023$3.94B-3.3%
Q2 FY2023Jun 30, 2023$3.92B-4.8%
Q1 FY2023Mar 31, 2023$3.73B-11.0%
Q4 FY2022Dec 31, 2022$3.88B-10.7%
Q3 FY2022Sep 30, 2022$4.08B-10.1%
Q2 FY2022Jun 30, 2022$4.12B-10.1%
Q1 FY2022Mar 31, 2022$4.19B-5.4%
Q4 FY2021Dec 31, 2021$4.34B+19.8%
Q3 FY2021Sep 30, 2021$4.54B+52.6%
Q2 FY2021Jun 30, 2021$4.58B+67.6%
Q1 FY2021Mar 31, 2021$4.43B+69.1%
Q4 FY2020Dec 31, 2020$3.62B–
Q3 FY2020Sep 30, 2020$2.97B–
Q2 FY2020Jun 30, 2020$2.73B–
Q1 FY2020Mar 31, 2020$2.62B–
Q3 FY2019Sep 29, 2019$0–
Q2 FY2019Jun 30, 2019$0–

More Viatris figures

See a number that looks wrong?